More current news:
Upcoming Trials Key For Endonovo And Its Time-Varying Electromagnetic Fields Technology
Aug. 8.16 | About: Endonovo Therapeutics, (ENDV)
Yash Bhatia
Yash Bhatia
Growth, growth at reasonable price, momentum, long only
(84 followers)
Summary
Endonovo’s Immunotronics and Cytotronics platforms are built upon technology discovered by NASA.
Specific magnetic fields have increased cell growth 400% and upregulated over 200 growth factors and cytokines.
For several reasons, TVEMF technology is superior to today’s commonly used pulsed electromagnetic field technology.
Acute liver failure and GvHD are gateway indications for Endonovo’s platforms.
Endonovo just signed an LOI to acquire RGN for $21.5 million, significantly boosting its asset base.
Outside of the energy sector, there probably hasn't been another under more pressure in the past year than that of biotechnology. As an example of the bearish bias, the ProShares Ultra NASDAQ Biotechnology ETF (NASDAQ: BIB) has slumped from a record high last July at $106.10 to as low as $33.97 late in June, representing a top-to-bottom decline of 68%. For the most part, biotechs of all sizes have felt the pain. Markets are always cyclical and I believe that the biotech beat down is reaching its bottom and will soon begin to reverse the trend. From a technical perspective, I think that BIB breaking over $50 again will be a sign of the reversal (it's currently around $43).
In my healthcare research, I try to stay diverse - i.e. finding small molecules, immunotherapy, devices, etc. - with large market potential. I think that with the recent rapid drop in the value of Endonovo Therapeutics (OTCQB: OTCQB:ENDV) that the company is worthy of additional due diligence. The company is developing innovative bioelectronics devices and therapies built upon its Time-Varying Electromagnetic Fields (TVEMF) technology for regenerative medicine. One of Endonovo's lead programs is the Immunotronics platform, a non-invasive, non-implantable bioelectronic device for treating and/or preventing vital organ failure via inflammation reduction, cell death and the promotion of cell regeneration. The initial focus of the company is to use the Immunotronics platform to treat acute and chronic inflammatory conditions of the liver.
Upcoming Trials Key For Endonovo And Its Time-Varying Electromagnetic Fields Technology
Aug. 8.16 | About: Endonovo Therapeutics, (ENDV)
Yash Bhatia
Yash Bhatia
Growth, growth at reasonable price, momentum, long only
(84 followers)
Summary
Endonovo’s Immunotronics and Cytotronics platforms are built upon technology discovered by NASA.
Specific magnetic fields have increased cell growth 400% and upregulated over 200 growth factors and cytokines.
For several reasons, TVEMF technology is superior to today’s commonly used pulsed electromagnetic field technology.
Acute liver failure and GvHD are gateway indications for Endonovo’s platforms.
Endonovo just signed an LOI to acquire RGN for $21.5 million, significantly boosting its asset base.
Outside of the energy sector, there probably hasn't been another under more pressure in the past year than that of biotechnology. As an example of the bearish bias, the ProShares Ultra NASDAQ Biotechnology ETF (NASDAQ: BIB) has slumped from a record high last July at $106.10 to as low as $33.97 late in June, representing a top-to-bottom decline of 68%. For the most part, biotechs of all sizes have felt the pain. Markets are always cyclical and I believe that the biotech beat down is reaching its bottom and will soon begin to reverse the trend. From a technical perspective, I think that BIB breaking over $50 again will be a sign of the reversal (it's currently around $43).
In my healthcare research, I try to stay diverse - i.e. finding small molecules, immunotherapy, devices, etc. - with large market potential. I think that with the recent rapid drop in the value of Endonovo Therapeutics (OTCQB: OTCQB:ENDV) that the company is worthy of additional due diligence. The company is developing innovative bioelectronics devices and therapies built upon its Time-Varying Electromagnetic Fields (TVEMF) technology for regenerative medicine. One of Endonovo's lead programs is the Immunotronics platform, a non-invasive, non-implantable bioelectronic device for treating and/or preventing vital organ failure via inflammation reduction, cell death and the promotion of cell regeneration. The initial focus of the company is to use the Immunotronics platform to treat acute and chronic inflammatory conditions of the liver.
